Abstracts tagged "Disease Activity"

Abstract Number: 635 • 2013 ACR/ARHP Annual Meeting
Multiple Altered Soluble Inflammatory Mediators Correlate With Disease Activity and Mark Impending Disease Flare In European-American Lupus Patients
Melissa E. Munroe¹, Jourdan R. Anderson², Krista M. Bean³, Joan T. Merrill⁴, Joel M. Guthridge³, Virginia C. Roberts³, Linda F. Thompson^5,6 and Judith A. James^4,7, ¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁶Immunobiology and Cancer, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁷College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: SLE is a waxing and waning disease characterized by immune dysregulation, major organ involvement, and disease flares. Identifying mechanistic mediators of altered disease activity…
Abstract Number: 2781 • 2013 ACR/ARHP Annual Meeting
The Disease Characteristics and Predictors Of Minimal Disease Activity On TNF Blockers- Results From A Longitudainal Observational Cohort
Amir Haddad¹, Arane Thavaneswaran¹, Ioana Ruiz Arruza², Vinod Chandran², Richard J. Cook³ and Dafna D. Gladman², ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada
Background/Purpose: A state of Minimal Disease Activity (MDA) has been defined and validated as a target for treatment in PsA. The purpose of the study…
Abstract Number: 2305 • 2013 ACR/ARHP Annual Meeting
Influence Of Disease Activity On The Physical Activity Of Rheumatoid Arthritis Patients
Vanesa Hernández-Hernández¹, Ivan Ferraz-Amaro², Esmeralda Delgado-Frías¹, Sagrario Bustabad-Reyes¹ and Federico Diaz-Gonzalez³, ¹Rheumatology, Hospital Universitario de Canarias, La Laguna, Spain, ²Rheumatology, Servicio de Reumatologia. Hospital Universitario de Canarias, Tenerife, Spain, ³Rheumatology, Servicio de Reumatologia.Hospital Universitario de Canarias, La Laguna, Spain
Background/Purpose: It is generally assumed that rheumatoid arthritis (RA) patients tend to exercise less than what is currently recommended. However, there is little data on…
Abstract Number: 1947 • 2013 ACR/ARHP Annual Meeting
The 7-Joint Ultrasound Score Is a Feasible Tool For Evaluating Joint Inflammation In Rheumatoid Arthritis Patients. Experience Among Rheumatologists With Basic Or Intermediate Level Of Ultrasound Training
Jana Hurnakova^1,2, Jakub Zavada^2,3, Herman F. Mann^1,2, Ladislav Senolt^2,4, Martin Klein^2,4, Petra Hanova^5,6, Sarka Forejtova^2,4, Marta Olejarova^2,4, Olga Ruzickova^2,4, Olga Sleglova^2,4 and Karel Pavelka^2,7, ¹Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Prague, Czech Republic, ²1st Faculty of Medicine, Charles University, Prague, Prague, Czech Republic, ³Charles University, Prague, Czech Republic, ⁴Institute of Rheumatology, Prague, Prague, Czech Republic, ⁵Institute of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Prague, Czech Republic, ⁶1st Faculty of Medicine, Charles University, Prague, Czech Republic, ⁷Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic
Background/Purpose: Musculoskeletal ultrasound plays an increasingly important role in monitoring disease activity and therapy response. German US-7 score is a recently introduced ultrasound scoring index…
Abstract Number: 1519 • 2013 ACR/ARHP Annual Meeting
Meeting The ACR 2010 Fibromyalgia Criteria Worsens Disease Activity and Quality Of Life In Patients With Axial Spondyloarthritis Treated With Infliximab
Mathieu Verdet¹, Clément Guillou², Julien Michaud¹, Christopher Banse¹, Sandra Desouches¹, Gilles Avenel³, Quentin Bréhier⁴, Aurélia Bisson-Vaivre¹, Sophie Pouplin¹ and Olivier Vittecoq⁵, ¹Rheumatology, Rouen University Hospital, Rouen, France, ²Inserm 905 & Institute for Biomedical Research, University of Rouen, Rouen, France, ³Rheumaotlogy, Rouen University Hospital, Rouen, France, ⁴Rheumatology, Le Havre Hospital, Le Havre, France, ⁵Rheumatology, Department of Rheumatology, Rouen University Hospital & Inserm 905, Institute for Biomedical Research, University of Rouen, Rouen, France
Background/Purpose: Managing axial spondyloarthritis (aSpA) may be difficult because sometimes patients are not good responder to anti-TNF. We made the hypothesis that in certain patients,…
Abstract Number: 1303 • 2013 ACR/ARHP Annual Meeting
Variations In Disease Activity and Therapeutic Management Of Rheumatoid Arthritis In Different International Regions: A Comparison Of Data From The Corrona International and Corrona United States Registries
Dimitrios A. Pappas¹, Kathy Lampl², Joel M. Kremer³, Sebastião C. Radominski⁴, Janos Gal⁵, Fredrik Nyberg⁶, Anand N. Malaviya⁷, Aimée Whitworth⁸, Oscar Luis Rillo⁹, Allan Gibofsky¹⁰, Tatiana Popkova¹¹, Meilien Ho¹², Ieda Laurindo¹³, George W. Reed⁸, Eduardo Mario Kerzberg¹⁴, Laura Horne¹⁵, Roman Záhora¹⁶, Katherine C. Saunders¹⁷, Bernado Pons-Estel¹⁸, Alina U. Onofrei¹⁹ and Jeffrey D. Greenberg²⁰, ¹Columbia University, New York, NY, ²AstraZeneca R&D Wilmington, Wilmington, DE, ³Center for Rheumatology, Albany Medical College, Albany, NY, ⁴Universidade Federal do Paraná, Curitiba, Brazil, ⁵Rheumatology, County Hospital, Kecskemet, Hungary, ⁶AstraZeneca R&D, Mölndal, Sweden, ⁷Rheumatology, Consultant Rheumatologist, ISIC Superspeciality Hospital, New Delhi-11007-, India, ⁸CORRONA, Inc., Southborough, MA, ⁹Hospital Tornú, Capital Federal, Argentina, ¹⁰Medicine and Public Health, Hospital for Special Surgery, New York, NY, ¹¹Research Institute of Rheumatology -Russian Academy of Medical Science, Moscow, Russia, ¹²AstraZeneca R&D Alderley Park, Macclesfield, United Kingdom, ¹³Rheumatology, Universidade de São Paulo, São Paulo, Brazil, ¹⁴Rheumatology, J. M. Ramos Mejía Hospital, School of Medicine, University of Buenos Aires, Buenos Aires, Argentina, ¹⁵AstraZeneca, Wilmington, DE, ¹⁶Revmatologická ambulance, Terezin, Czech Republic, ¹⁷Corrona, LLC., Southborough, MA, ¹⁸Hospital Provincial de Rosario, Rosario, Argentina, ¹⁹University of Massachusetts Medical School, Worcester, MA, ²⁰Rheumatology, NYU Hospital for Joint Diseases, New York, NY
Background/Purpose: The CORRONA International (C.Intl) rheumatoid arthritis (RA) registry is the first multinational RA registry uniformly collecting baseline and longitudinal data. We explored variations in…
Abstract Number: 522 • 2013 ACR/ARHP Annual Meeting
Abatacept Reduces Disease Activity In Early Primary Sjögren’s Syndrome:One Year Results From a Phase II Open-Label Study
PM Meiners¹, A Vissink², Fkl Spijkervet³, EA Haacke⁴, WH Abdulahad⁵, E Brouwer⁵, MG Huitema⁵, N Sillevis Smitt-Kamminga⁶, FGM Kroese⁷, S Arends⁵ and H Bootsma⁵, ¹Oral and Maxillofacial Surgery, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ²Oral and Maxillofacial Surgery, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ³Oral and Maxillofacial Surgery, University Medical Center Groningen, Groningen, Netherlands, ⁴Pathology, University Medical Center Groningen, Groningen, Netherlands, ⁵Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, ⁶Opthalmology, University Medical Center Groningen, Groningen, Netherlands, ⁷Rheumatology and clinical immunology, University Medical Center Groningen, Groningen, Netherlands
Background/Purpose: Traditional DMARDs have limited effects in primary Sjögren's (pSS) patients. B cell depletion therapy with rituximab showed efficacy, but had some side-effects. T and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.